Fasudil hydrochloride cas: 105628-07-7

CAS NO: 105628-07-7
Fasudil hydrochloride
Description Review
Description

Fasudil hydrochloride Hcl is a small molecule inhibitor produced by Asahi Kasei Pharma. It has been shown to have therapeutic potential in various diseases, including stroke, pulmonary hypertension, and Alzheimer's disease. The chemical name of Fasudil hydrochloride Hcl is 5-(1,4-Diazepane-1-sulfonyl)isoquinoline hydrochloride. Its molecular formula is C14H17N3O2S•HCl, its formula weight is 327.83g/mol, and its CAS number is 105628-07-7.

Top Ten Keywords and Synonyms

According to a Google search for Fasudil hydrochloride Hcl, these are the top ten keywords related to it: "stroke", "pulmonary hypertension", "Alzheimer's disease", "cerebral vasospasm", "central nervous system disorders", "clinical trial", "neuroprotection", "ischemia-reperfusion injury", "vascular smooth muscle cells", and "protein kinase inhibitor".

Some of the Synonyms for Fasudil hydrochloride Hcl include HA1077, AT877, MEK-IN-1, HA 1077 hydrochloride, and (5-Isoquinolinesulfonyl)-1,4-diazepane hydrochloride.

Health Benefits of Fasudil Hydrochloride Hcl

Fasudil hydrochloride Hcl has been shown to have beneficial effects in the treatment of various diseases such as stroke, pulmonary hypertension, and Alzheimer's disease. It can improve blood flow, reduce inflammation, and protect brain cells from damage. Fasudil hydrochloride Hcl has also been found to have anti-proliferative effects on cancer cells and may have a potential role in cancer treatment.

Potential Effects

Fasudil hydrochloride Hcl is a potent inhibitor of Rho-associated protein kinases (ROCKs), which are involved in the regulation of cellular processes such as smooth muscle contraction, cell adhesion, and cell proliferation. By inhibiting ROCKs, Fasudil hydrochloride Hcl can improve blood flow, reduce inflammation, and protect cells from damage in various diseases. Fasudil hydrochloride Hcl may also act as a neuroprotective agent by inhibiting the formation of toxic protein aggregates in the brain.

Product Mechanism

The molecular mechanism of Fasudil hydrochloride Hcl involves the inhibition of ROCKs, which are a family of serine/threonine kinases that play a critical role in cellular processes such as cytoskeleton remodeling, cell motility, and cell proliferation. By inhibiting ROCK activity, Fasudil hydrochloride Hcl can relax vascular smooth muscle cells, improve blood flow, reduce inflammation, and protect cells from injury in various disease conditions.

Safety of Fasudil Hydrochloride Hcl

Studies of Fasudil hydrochloride Hcl have shown that it can be administered safely to humans at doses that induce therapeutic effects. Fasudil hydrochloride Hcl has been given safely to patients in clinical trials of stroke, pulmonary hypertension, and Alzheimer's disease. In general, it is well tolerated, and most adverse events are mild and transient.

Side Effects

The side effects of Fasudil hydrochloride Hcl are generally mild, with the most common side effects being headache, dizziness, and nausea. Rarely, Fasudil hydrochloride Hcl can cause hypotension and bradycardia, and caution should be exercised when administering Fasudil hydrochloride Hcl to patients with cardiovascular disease.

Dosing Information

The dosage of Fasudil hydrochloride Hcl varies depending on the disease being treated and the patient's condition. In clinical trials, doses ranging from 15 mg/d to 60 mg/d have been used, and the duration of treatment varies depending on the disease being treated.

Conclusion

Fasudil hydrochloride Hcl is a promising therapeutic agent with a broad range of clinical applications. As a ROCK inhibitor, it has been shown to have potential benefits in the treatment of various diseases such as stroke, pulmonary hypertension, and Alzheimer's disease. Fasudil hydrochloride Hcl has also been found to have anti-proliferative effects on cancer cells and may have a potential role in cancer treatment. Ongoing research continues to provide more insights into its efficacy and safety profile. With further clinical trials, Fasudil hydrochloride Hcl may develop into a significant drug for treating a variety of diseases.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code